5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 5.64▼ | 5.65▼ | 5.64▼ | 5.94▼ | 7.09▼ |
MA10 | 5.65▼ | 5.67▼ | 5.73▼ | 6.04▼ | 6.79▼ |
MA20 | 5.64▼ | 5.76▼ | 5.88▼ | 6.93▼ | 6.45▼ |
MA50 | 5.66▼ | 5.97▼ | 6.09▼ | 6.59▼ | 4.79▲ |
MA100 | 5.74▼ | 6.09▼ | 6.64▼ | 6.38▼ | 6.92▼ |
MA200 | 5.87▼ | 6.70▼ | 6.99▼ | 5.12▲ | 10.97▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.002▼ | 0.000▼ | -0.020▼ | -0.179▼ | -0.075▼ |
RSI | 36.911▼ | 33.528▼ | 31.678▼ | 36.602▼ | 46.640▼ |
STOCH | 40.143 | 20.374 | 12.939▼ | 12.002▼ | 63.941 |
WILL %R | -95.000▼ | -96.875▼ | -97.619▼ | -99.432▼ | -73.529 |
CCI | -214.235▼ | -105.676▼ | -99.670 | -85.585 | -68.519 |
Monday, June 02, 2025 09:41 AM
Verastem's GFH375 trial data at ASCO 2025 shows a 52% response rate in pancreatic cancer and no dose-limiting toxicities across tested doses.
|
Wednesday, May 28, 2025 07:43 AM
Verastem Oncology VSTM shares rallied 22.2% in a month, primarily driven by the FDA approval of the company’s novel combination regimen of avutometinib plus defactinib in early May for treating ...
|
Thursday, May 08, 2025 05:00 PM
The latest price target for Verastem (NASDAQ:VSTM) was reported by HC Wainwright & Co. on May 9, 2025. The analyst firm set a price target for $14.00 expecting VSTM to rise to within 12 months (a ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 5.78 | 5.84 | 5.58 | 5.60 | 1,298,700 |
12/06/25 | 5.88 | 6.01 | 5.81 | 5.88 | 1,619,700 |
11/06/25 | 6.22 | 6.30 | 5.97 | 5.97 | 1,469,700 |
10/06/25 | 6.14 | 6.30 | 6.095 | 6.13 | 881,216 |
09/06/25 | 6.465 | 6.48 | 6.07 | 6.11 | 1,065,944 |
06/06/25 | 6.30 | 6.62 | 6.18 | 6.42 | 1,557,300 |
05/06/25 | 6.23 | 6.23 | 5.89 | 6.18 | 1,195,200 |
04/06/25 | 5.952 | 6.33 | 5.875 | 6.17 | 1,945,711 |
03/06/25 | 6.03 | 6.1441 | 5.725 | 5.90 | 2,631,691 |
02/06/25 | 7.60 | 7.87 | 5.80 | 6.02 | 10,460,559 |
|
|
||||
|
|
||||
|
|